A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen

1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butaned...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of applied toxicology 2006-01, Vol.26 (1), p.72-80
1. Verfasser: Irwin, Richard D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 80
container_issue 1
container_start_page 72
container_title Journal of applied toxicology
container_volume 26
creator Irwin, Richard D.
description 1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/jat.1110
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19712893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14772338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</originalsourceid><addsrcrecordid>eNqF0VtPFDEUB_DGaGQBEz-B6YuGBwd7mZm2jxvCVRBNUHlrzrQdLM5O17YL8u3pZifwZHzq7Zdz2n8RekvJPiWEfbqFvE8pJS_QjBKlKspa_hLNCGtJVXNxvYW2U7olpJwx-Rpt0ZYq3vB6hn7McXR33t3j0OMysW40Dg8OrB9vcA44_3J4GZ31JvswliVkTD_WVbfKMJbtMGCf8BgyBmwgGj-GGzfuolc9DMm9mcYd9P3o8OrgpDq_PD49mJ9XppacVKIxnRK17BUAsURYDr0hEmwHZatjwNuO9MpJUytrXNNQ2TZGUiZYea2VfAd92NRdxvBn5VLWC5-MG4Zyt7BKmipBmVT8_7AWgnG-rri3gSaGlKLr9TL6BcQHTYleh61L2HoddqHvppqrbuHsM5zSLeD9BCAZGPoIo_Hp2YmasfIpxVUbd-8H9_DPhvpsfjU1nrxP2f198hB_61Zw0eifX47157OTr0cX198054_piqNa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14772338</pqid></control><display><type>article</type><title>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Irwin, Richard D.</creator><creatorcontrib>Irwin, Richard D.</creatorcontrib><description>1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0260-437X</identifier><identifier>EISSN: 1099-1263</identifier><identifier>DOI: 10.1002/jat.1110</identifier><identifier>PMID: 16193534</identifier><identifier>CODEN: JJATDK</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>1.4-butanediol ; 4-Butyrolactone - toxicity ; Animals ; Biological and medical sciences ; Biotransformation ; Butylene Glycols - pharmacokinetics ; Butylene Glycols - toxicity ; Carcinogenesis, carcinogens and anticarcinogens ; carcinogenicity ; Carcinogenicity Tests ; Chemical agents ; Humans ; Hydroxybutyrates - metabolism ; Hydroxybutyrates - toxicity ; Medical sciences ; metabolism ; Solvents - toxicity ; Toxicology ; Tumors ; γ-butyrolactone ; γ-hydroxybutyric acid</subject><ispartof>Journal of applied toxicology, 2006-01, Vol.26 (1), p.72-80</ispartof><rights>Copyright © 2005 John Wiley &amp; Sons, Ltd.</rights><rights>2006 INIST-CNRS</rights><rights>2005 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</citedby><cites>FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjat.1110$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjat.1110$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17422000$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16193534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Irwin, Richard D.</creatorcontrib><title>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</title><title>Journal of applied toxicology</title><addtitle>J. Appl. Toxicol</addtitle><description>1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><subject>1.4-butanediol</subject><subject>4-Butyrolactone - toxicity</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biotransformation</subject><subject>Butylene Glycols - pharmacokinetics</subject><subject>Butylene Glycols - toxicity</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>carcinogenicity</subject><subject>Carcinogenicity Tests</subject><subject>Chemical agents</subject><subject>Humans</subject><subject>Hydroxybutyrates - metabolism</subject><subject>Hydroxybutyrates - toxicity</subject><subject>Medical sciences</subject><subject>metabolism</subject><subject>Solvents - toxicity</subject><subject>Toxicology</subject><subject>Tumors</subject><subject>γ-butyrolactone</subject><subject>γ-hydroxybutyric acid</subject><issn>0260-437X</issn><issn>1099-1263</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0VtPFDEUB_DGaGQBEz-B6YuGBwd7mZm2jxvCVRBNUHlrzrQdLM5O17YL8u3pZifwZHzq7Zdz2n8RekvJPiWEfbqFvE8pJS_QjBKlKspa_hLNCGtJVXNxvYW2U7olpJwx-Rpt0ZYq3vB6hn7McXR33t3j0OMysW40Dg8OrB9vcA44_3J4GZ31JvswliVkTD_WVbfKMJbtMGCf8BgyBmwgGj-GGzfuolc9DMm9mcYd9P3o8OrgpDq_PD49mJ9XppacVKIxnRK17BUAsURYDr0hEmwHZatjwNuO9MpJUytrXNNQ2TZGUiZYea2VfAd92NRdxvBn5VLWC5-MG4Zyt7BKmipBmVT8_7AWgnG-rri3gSaGlKLr9TL6BcQHTYleh61L2HoddqHvppqrbuHsM5zSLeD9BCAZGPoIo_Hp2YmasfIpxVUbd-8H9_DPhvpsfjU1nrxP2f198hB_61Zw0eifX47157OTr0cX198054_piqNa</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>Irwin, Richard D.</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>C1K</scope><scope>SOI</scope><scope>7U7</scope></search><sort><creationdate>200601</creationdate><title>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</title><author>Irwin, Richard D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4830-75cb9748f9aa0d07d3afc08adbaf9ab2a36b0f9e8c49dce551865c81272110d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>1.4-butanediol</topic><topic>4-Butyrolactone - toxicity</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biotransformation</topic><topic>Butylene Glycols - pharmacokinetics</topic><topic>Butylene Glycols - toxicity</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>carcinogenicity</topic><topic>Carcinogenicity Tests</topic><topic>Chemical agents</topic><topic>Humans</topic><topic>Hydroxybutyrates - metabolism</topic><topic>Hydroxybutyrates - toxicity</topic><topic>Medical sciences</topic><topic>metabolism</topic><topic>Solvents - toxicity</topic><topic>Toxicology</topic><topic>Tumors</topic><topic>γ-butyrolactone</topic><topic>γ-hydroxybutyric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Irwin, Richard D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Environment Abstracts</collection><collection>Toxicology Abstracts</collection><jtitle>Journal of applied toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Irwin, Richard D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen</atitle><jtitle>Journal of applied toxicology</jtitle><addtitle>J. Appl. Toxicol</addtitle><date>2006-01</date><risdate>2006</risdate><volume>26</volume><issue>1</issue><spage>72</spage><epage>80</epage><pages>72-80</pages><issn>0260-437X</issn><eissn>1099-1263</eissn><coden>JJATDK</coden><abstract>1,4‐Butanediol is an industrial chemical used primarily as an intermediate in the manufacture of other organic chemicals. It has recently been associated with deaths, addiction and withdrawal related to its promotion and use as a dietary supplement. The rapid absorption and conversion of 1,4‐butanediol to γ‐hydroxybutyric acid (GHB, or date rape drug) in animals and humans is well documented and is the basis for its abuse potential. A disposition and metabolism study conducted in F344 rats by the National Toxicology Program (NTP) confirmed the rapid conversion of 1‐14C‐1,4‐butanediol to 14CO2. Because of this, the toxicological profile of 1,4‐butanediol resembles that of γ‐hydroxybutyric acid. Gamma‐hydroxybutyric acid occurs naturally in the brain and peripheral tissues and is converted to succinate and metabolized through the TCA cycle. Although the function of γ‐hydroxybutyric acid in peripheral tissues is not known, the presence of specific high affinity receptors for γ‐hydroxybutyric acid suggests that it functions as a neuromodulator in the brain and neuronal tissue. Gamma‐hydroxybutyric acid readily crosses the blood–brain barrier and elicits characteristic neuropharmacologic responses after oral, i.p., or i.v. administration. The same responses are observed after administration of 1,4‐butanediol. The cyclic lactone of γ‐hydroxybutyric acid, γ‐butyrolactone, is also rapidly converted to γ‐hydroxybutyric acid by enzymes in the blood and liver in animals and humans, and produces pharmacological effects identical to those produced by 1,4‐butanediol and γ‐hydroxybutyric acid. γ‐Butyrolactone was previously evaluated by the NTP in 14‐day and 13‐week prechronic toxicology studies and in 2‐year chronic toxicology and carcinogenesis studies in F344 rats and B6C3F1 mice. No organ specific toxicity occurred. In the carcinogenesis studies there was an equivocal response in male mice based on a marginal increase in the incidence of pheochromocytomas of the adrenal medulla. Because the absence of chronic toxicity and significant carcinogenicity of γ‐hydroxybutyric acid were established in NTP prechronic and chronic studies with γ‐butyrolactone, it is concluded that similar results would be obtained in a 2‐year study with 1,4‐butanediol, and that 1,4‐butanediol is not a carcinogen. Copyright © 2005 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>16193534</pmid><doi>10.1002/jat.1110</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0260-437X
ispartof Journal of applied toxicology, 2006-01, Vol.26 (1), p.72-80
issn 0260-437X
1099-1263
language eng
recordid cdi_proquest_miscellaneous_19712893
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects 1.4-butanediol
4-Butyrolactone - toxicity
Animals
Biological and medical sciences
Biotransformation
Butylene Glycols - pharmacokinetics
Butylene Glycols - toxicity
Carcinogenesis, carcinogens and anticarcinogens
carcinogenicity
Carcinogenicity Tests
Chemical agents
Humans
Hydroxybutyrates - metabolism
Hydroxybutyrates - toxicity
Medical sciences
metabolism
Solvents - toxicity
Toxicology
Tumors
γ-butyrolactone
γ-hydroxybutyric acid
title A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T18%3A07%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20of%20evidence%20leading%20to%20the%20prediction%20that%201,4-butanediol%20is%20not%20a%20carcinogen&rft.jtitle=Journal%20of%20applied%20toxicology&rft.au=Irwin,%20Richard%20D.&rft.date=2006-01&rft.volume=26&rft.issue=1&rft.spage=72&rft.epage=80&rft.pages=72-80&rft.issn=0260-437X&rft.eissn=1099-1263&rft.coden=JJATDK&rft_id=info:doi/10.1002/jat.1110&rft_dat=%3Cproquest_cross%3E14772338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14772338&rft_id=info:pmid/16193534&rfr_iscdi=true